| Symbol | CYTK |
|---|---|
| Name | CYTOKINETICS INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA 94080 |
| Telephone | (650) 624-3000 |
| Fax | — |
| — | |
| Website | https://www.cytokinetics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001061983 |
| Description | Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. Additional info from NASDAQ: |
2026-08-20 11:30
Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
Read more
2026-08-18 20:38
Malik Fady Ibraham 🟡 adjusted position in 3.5K shares (1 derivative) of CYTOKINETICS INC (CYTK) at $75.82 Transaction Date: Aug 18, 2026 | Filing ID: 000088
Read more
2026-08-18 20:00
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read more
2026-08-13 13:25
(99% Neutral) CYTOKINETICS INC (CYTK) Announces Update on Collaboration with Oyster Point Boulevard South San Francisco
Read more
2026-08-10 21:11
Director Blum Robert I 🟡 adjusted position in 7.5K shares (1 derivative) of CYTOKINETICS INC (CYTK) at $76.76 Transaction Date: Aug 10, 2026 | Filing ID: 000087
Read more
2026-07-30 20:26
Callos Andrew 🟡 adjusted position in 14.0K shares (1 derivative) of CYTOKINETICS INC (CYTK) at $79.88 ($1.8M) Transaction Date: Jul 30, 2026 | Filing ID: 000086
Read more
2026-07-30 20:22
📋 ANDREW CALLOS (Officer) plans to sell 24K shares of CYTOKINETICS, INCORPORATED (at $78.39 each, total $1.9M) Filed: Jul 30, 2026 | ID: 007436
Read more
2026-07-30 10:20
Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales
Read more
2026-07-27 20:33
Director Blum Robert I 🟡 adjusted position in 7.5K shares (1 derivative) of CYTOKINETICS INC (CYTK) at $80.87 Transaction Date: Jul 27, 2026 | Filing ID: 000085
Read more
2026-07-23 20:09
Malik Fady Ibraham 🟡 adjusted position in 3.5K shares (1 derivative) of CYTOKINETICS INC (CYTK) at $80.59 Transaction Date: Jul 21, 2026 | Filing ID: 000084
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07600177 | Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Ca… | Phase4 | Hypertrophic Cardiomyopathy (HCM) | Recruiting | 2026-05-05 | 2027-03-15 | ClinicalTrials.gov |
| NCT07054073 | HCMR Re-Imaging Study | — | Hypertrophic Cardiomyopathy (HCM) | Recruiting | 2026-03-30 | 2027-07-01 | ClinicalTrials.gov |
| NCT06793371 | AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of … | Phase2 | Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) | Recruiting | 2025-02-06 | 2026-09-01 | ClinicalTrials.gov |
| NCT06736574 | Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With … | Phase3 | Heart Failure | Recruiting | 2024-12-19 | 2027-12-01 | ClinicalTrials.gov |
| NCT06412666 | A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptoma… | Phase2 | Pediatric | Active_Not_Recruiting | 2024-05-29 | 2030-01-01 | ClinicalTrials.gov |
| NCT06081894 | A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in… | Phase3 | Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy | Active_Not_Recruiting | 2023-08-31 | 2026-10-01 | ClinicalTrials.gov |
| NCT05767346 | Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Meto… | Phase3 | Obstructive Hypertrophic Cardiomyopathy (oHCM) | Completed | 2023-06-20 | 2025-03-28 | ClinicalTrials.gov |
| NCT05924815 | Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval | Phase1 | Healthy Participants | Completed | 2023-05-15 | 2023-11-14 | ClinicalTrials.gov |
| NCT05877053 | A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Parti… | Phase1 | Healthy Participants | Completed | 2023-05-09 | 2024-11-20 | ClinicalTrials.gov |
| NCT05662215 | A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Parti… | Phase1 | Healthy Participants | Terminated | 2022-12-06 | 2023-08-08 | ClinicalTrials.gov |
| NCT05442775 | A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031) | Phase3 | Amyotrophic Lateral Sclerosis | Terminated | 2022-08-04 | 2023-06-07 | ClinicalTrials.gov |
| NCT05186818 | Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Plac… | Phase3 | Obstructive Hypertrophic Cardiomyopathy (oHCM) | Completed | 2022-02-01 | 2023-12-18 | ClinicalTrials.gov |
| NCT04944784 | A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amy… | Phase3 | Amyotrophic Lateral Sclerosis | Terminated | 2021-08-16 | 2023-07-18 | ClinicalTrials.gov |
| NCT04848506 | Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of… | Phase2 | Symptomatic Hypertrophic Cardiomyopathy (HCM) | Enrolling_By_Invitation | 2021-05-06 | 2028-03-01 | ClinicalTrials.gov |
| NCT04783766 | Safety, Tolerability and Pharmacokinetics Study of CK-3773274 | Phase1 | Obstructive Hypertrophic Cardiomyopathy | Completed | 2021-04-10 | 2021-08-05 | ClinicalTrials.gov |
| NCT04464525 | Omecamtiv Mecarbil Post-trial Access Study | Phase3 | Chronic Heart Failure With Reduced Ejection Fraction | Withdrawn | 2020-12-18 | 2026-11-27 | ClinicalTrials.gov |
| NCT04219826 | Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and … | Phase2 | Hypertrophic Cardiomyopathy (HCM) | Completed | 2020-01-10 | 2023-02-28 | ClinicalTrials.gov |
| NCT04175808 | Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in He… | Phase1 | QT Intervals Changes | Completed | 2019-11-14 | 2020-03-04 | ClinicalTrials.gov |
| NCT03759392 | Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjec… | Phase3 | Heart Failure With Reduced Ejection Fraction | Completed | 2019-04-09 | 2022-01-06 | ClinicalTrials.gov |
| NCT03767855 | A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subje… | Phase1 | Symptomatic Obstructive Hypertrophic Cardiomyopathy | Completed | 2018-12-04 | 2020-01-03 | ClinicalTrials.gov |
| NCT03160898 | A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients… | Phase2 | Amyotrophic Lateral Sclerosis | Completed | 2017-07-24 | 2019-03-07 | ClinicalTrials.gov |
| NCT03065959 | A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male an… | Phase1 | Mobility Limitation | Terminated | 2017-06-28 | 2018-10-10 | ClinicalTrials.gov |
| NCT02929329 | Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart F… | Phase3 | Heart Failure | Completed | 2017-01-06 | 2020-09-14 | ClinicalTrials.gov |
| NCT02936635 | A Study for Patients Who Completed VITALITY-ALS (CY 4031) | Phase3 | Amyotrophic Lateral Sclerosis (ALS) | Completed | 2016-10-17 | 2018-10-26 | ClinicalTrials.gov |
| NCT02662582 | A Study to Assess the Effect of CK-2127107 on Physical Function in Subjects Wit… | Phase2 | Chronic Obstructive Pulmonary Disease (COPD) | Completed | 2016-06-30 | 2018-06-08 | ClinicalTrials.gov |
| NCT02695420 | Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart … | Phase2 | Heart Failure With Reduced Ejection Fraction | Completed | 2016-04-14 | 2017-05-08 | ClinicalTrials.gov |
| NCT02644668 | A Study of CK-2127107 in Patients With Spinal Muscular Atrophy | Phase2 | Spinal Muscular Atrophy | Completed | 2016-01-14 | 2018-05-31 | ClinicalTrials.gov |
| NCT02601001 | Pharmacokinetics and Safety Study of Omecamtiv Mecarbil in Healthy Japanese Adu… | Phase1 | Healthy Volunteer | Completed | 2015-11-13 | 2016-01-06 | ClinicalTrials.gov |
| NCT02496767 | Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices … | Phase3 | Amyotrophic Lateral Sclerosis | Completed | 2015-09-03 | 2017-09-27 | ClinicalTrials.gov |
| NCT01786512 | COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility i… | Phase2 | Modified Release Oral Formulation | Completed | 2013-02-26 | 2015-08-19 | ClinicalTrials.gov |
| NCT01737866 | Pharmacokinetics Study of AMG 423 in Healthy Subjects and Subjects With Various… | Phase1 | Heart Failure | Completed | 2012-11-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01709149 | Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral S… | Phase2 | Amyotrophic Lateral Sclerosis | Completed | 2012-10-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01486849 | Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With … | Phase2 | Amyotrophic Lateral Sclerosis | Completed | 2011-11-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01378676 | A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients Wit… | Phase2 | Amyotrophic Lateral Sclerosis | Completed | 2011-06-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01300013 | Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamt… | Phase2 | Heart Failure | Completed | 2011-04-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01268280 | Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gra… | Phase2 | Myasthenia Gravis | Terminated | 2010-12-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01077167 | Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure Patients | Phase2 | Heart Failure | Withdrawn | 2010-07-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT01131013 | A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomati… | Phase2 | Intermittent Claudication | Completed | 2010-05-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT01089010 | A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) | Phase2 | Amyotrophic Lateral Sclerosis | Completed | 2010-03-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00941681 | Pharmacokinetics of Oral CK-1827452 in Patients With Stable Heart Failure | Phase2 | Heart Failure | Completed | 2009-04-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00748579 | Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency | Phase2 | Heart Failure | Terminated | 2008-09-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00682565 | PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiom… | Phase2 | Heart Failure | Completed | 2008-04-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00607841 | A Study of Ispinesib in Metastatic Breast Cancer | Phase1 | Breast Neoplasms | Terminated | 2007-12-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00624442 | A Study of CK-1827452 Infusion in Stable Heart Failure | Phase2 | Heart Failure | Completed | 2007-04-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00343564 | A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma | Phase1 | Non-Hodgkin's Lymphoma | Completed | 2006-04-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT01380223 | A Pharmacokinetic and Pharmacodynamic Study of Omecamtiv Mecarbil in Healthy Vo… | Phase1 | Heart Failure | Completed | 2005-08-01 | 2006-04-01 | ClinicalTrials.gov |
Total clinical trials: 46
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE3 | Heart Failure | RECRUITING | NCT06736574 |
| Omecamtiv Mecarbil (OM) | Other | Phase PHASE3 | Heart Failure | RECRUITING | NCT06736574 |
| Placebo | Other | Phase PHASE2 | Pediatric | ACTIVE_NOT_RECRUITING | NCT06412666 |
| Aficamten | Other | Phase PHASE2 | Pediatric | ACTIVE_NOT_RECRUITING | NCT06412666 |
| Placebo | Other | Phase PHASE3 | Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy | ACTIVE_NOT_RECRUITING | NCT06081894 |
| Aficamten | Other | Phase PHASE3 | Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy | ACTIVE_NOT_RECRUITING | NCT06081894 |
| Placebo | Other | Phase PHASE3 | Heart Failure | RECRUITING | NCT06736574 |
| Omecamtiv Mecarbil (OM) | Other | Phase PHASE3 | Heart Failure | RECRUITING | NCT06736574 |
| Placebo | Other | Phase PHASE3 | Heart Failure | RECRUITING | NCT06736574 |
| Omecamtiv Mecarbil (OM) | Other | Phase PHASE3 | Heart Failure | RECRUITING | NCT06736574 |
| Placebo | Other | Phase PHASE3 | Heart Failure | RECRUITING | NCT06736574 |
| Omecamtiv Mecarbil (OM) | Other | Phase PHASE3 | Heart Failure | RECRUITING | NCT06736574 |
| Placebo | Other | Phase PHASE3 | Heart Failure | RECRUITING | NCT06736574 |
| Omecamtiv Mecarbil (OM) | Other | Phase PHASE3 | Heart Failure | RECRUITING | NCT06736574 |
| Placebo to match metoprolol succinate | Other | Phase PHASE3 | Obstructive Hypertrophic Cardiomyopathy (oHCM) | COMPLETED | NCT05767346 |
| Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg) | Other | Phase PHASE3 | Obstructive Hypertrophic Cardiomyopathy (oHCM) | COMPLETED | NCT05767346 |
| Placebo to match aficamten | Other | Phase PHASE3 | Obstructive Hypertrophic Cardiomyopathy (oHCM) | COMPLETED | NCT05767346 |
| Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg) | Other | Phase PHASE3 | Obstructive Hypertrophic Cardiomyopathy (oHCM) | COMPLETED | NCT05767346 |
| Placebo to match CK-4021586 | Other | Phase PHASE2 | Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) | RECRUITING | NCT06793371 |
| CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg) | Other | Phase PHASE2 | Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) | RECRUITING | NCT06793371 |
| Aficamten | Other | Phase PHASE4 | Hypertrophic Cardiomyopathy (HCM) | RECRUITING | NCT07600177 |
| Aficamten | Other | Phase PHASE4 | Hypertrophic Cardiomyopathy (HCM) | RECRUITING | NCT07600177 |
| Aficamten | Other | Phase PHASE4 | Hypertrophic Cardiomyopathy (HCM) | RECRUITING | NCT07600177 |
| Aficamten | Other | Phase PHASE4 | Hypertrophic Cardiomyopathy (HCM) | RECRUITING | NCT07600177 |
| Aficamten | Other | Phase PHASE4 | Hypertrophic Cardiomyopathy (HCM) | RECRUITING | NCT07600177 |
| Aficamten | Other | Phase PHASE4 | Hypertrophic Cardiomyopathy (HCM) | RECRUITING | NCT07600177 |
| Aficamten | Other | Phase PHASE4 | Hypertrophic Cardiomyopathy (HCM) | RECRUITING | NCT07600177 |
| Aficamten | Other | Phase PHASE4 | Hypertrophic Cardiomyopathy (HCM) | RECRUITING | NCT07600177 |
| Aficamten | Other | Phase PHASE4 | Hypertrophic Cardiomyopathy (HCM) | RECRUITING | NCT07600177 |
| Aficamten | Other | Phase PHASE4 | Hypertrophic Cardiomyopathy (HCM) | RECRUITING | NCT07600177 |
| Aficamten | Other | Phase PHASE4 | Hypertrophic Cardiomyopathy (HCM) | RECRUITING | NCT07600177 |
| Aficamten | Other | Phase PHASE4 | Hypertrophic Cardiomyopathy (HCM) | RECRUITING | NCT07600177 |
| CK-1827452 | Other | Phase PHASE2 | Heart Failure | COMPLETED | NCT00941681 |
| CK-1827452 | Other | Phase PHASE2 | Heart Failure | COMPLETED | NCT00941681 |
| omecamtiv mecarbil | Other | Phase PHASE1 | Heart Failure | COMPLETED | NCT01380223 |
| placebo | Other | Phase PHASE1 | Heart Failure | COMPLETED | NCT01380223 |
| omecamtiv mecarbil | Other | Phase PHASE1 | Heart Failure | COMPLETED | NCT01380223 |
| placebo | Other | Phase PHASE1 | Heart Failure | COMPLETED | NCT01380223 |
| omecamtiv mecarbil | Other | Phase PHASE1 | Heart Failure | COMPLETED | NCT01380223 |
| placebo | Other | Phase PHASE1 | Heart Failure | COMPLETED | NCT01380223 |
| Placebo capsule | Other | Phase PHASE2 | Heart Failure | COMPLETED | NCT00682565 |
| Placebo iv infusion | Other | Phase PHASE2 | Heart Failure | COMPLETED | NCT00682565 |
| CK-1827452 25mg capsule | Other | Phase PHASE2 | Heart Failure | COMPLETED | NCT00682565 |
| CK-1827452 48 mg and 11 mg iv infusion | Other | Phase PHASE2 | Heart Failure | COMPLETED | NCT00682565 |
| CK-1827452 12.5mg capsule | Other | Phase PHASE2 | Heart Failure | COMPLETED | NCT00682565 |
| CK-1827452 24mg and 6 mg iv infusion | Other | Phase PHASE2 | Heart Failure | COMPLETED | NCT00682565 |
| Riluzole 50 MG | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01486849 |
| Placebo | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01486849 |
| CK-2017357 | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01486849 |
| Riluzole 50 MG | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01486849 |
| Placebo | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01486849 |
| CK-2017357 | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01486849 |
| Riluzole 50 MG | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01486849 |
| Placebo | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01486849 |
| CK-2017357 | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01486849 |
| Ispinesib | Other | Phase PHASE1 | Breast Neoplasms | TERMINATED | NCT00607841 |
| Ispinesib | Other | Phase PHASE1 | Breast Neoplasms | TERMINATED | NCT00607841 |
| CK-2017357 (Part B) | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01378676 |
| Placebo (Part B) | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01378676 |
| Riluzole 50 MG (Part B) | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01378676 |
| CK-2017357 (Part A) | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01378676 |
| Placebo (Part A) | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01378676 |
| CK-2017357 (Part B) | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01378676 |
| Placebo (Part B) | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01378676 |
| Riluzole 50 MG (Part B) | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01378676 |
| CK-2017357 (Part A) | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01378676 |
| Placebo (Part A) | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01378676 |
| 500 mg CK-2017357 | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01089010 |
| 250 mg CK-2017357 | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01089010 |
| Placebo | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01089010 |
| 500 mg CK-2017357 | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01089010 |
| 250 mg CK-2017357 | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01089010 |
| Placebo | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01089010 |
| 500 mg CK-2017357 | Other | Phase PHASE2 | Intermittent Claudication | COMPLETED | NCT01131013 |
| 375 mg CK-2017357 | Other | Phase PHASE2 | Intermittent Claudication | COMPLETED | NCT01131013 |
| Placebo | Other | Phase PHASE2 | Intermittent Claudication | COMPLETED | NCT01131013 |
| 500 mg CK-2017357 | Other | Phase PHASE2 | Intermittent Claudication | COMPLETED | NCT01131013 |
| 375 mg CK-2017357 | Other | Phase PHASE2 | Intermittent Claudication | COMPLETED | NCT01131013 |
| Placebo | Other | Phase PHASE2 | Intermittent Claudication | COMPLETED | NCT01131013 |
| 500 mg CK-2017357 | Other | Phase PHASE2 | Myasthenia Gravis | TERMINATED | NCT01268280 |
| 250 mg CK-2017357 | Other | Phase PHASE2 | Myasthenia Gravis | TERMINATED | NCT01268280 |
| Placebo | Other | Phase PHASE2 | Myasthenia Gravis | TERMINATED | NCT01268280 |
| SB-743921 | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00343564 |
| SB-743921 | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00343564 |
| CK-1827452 | Other | Phase PHASE2 | Heart Failure | TERMINATED | NCT00748579 |
| CK-1827452 | Other | Phase PHASE2 | Heart Failure | TERMINATED | NCT00748579 |
| Riluzole | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01709149 |
| Placebo tablets | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01709149 |
| CK-2017357 | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01709149 |
| Riluzole | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01709149 |
| Placebo tablets | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01709149 |
| CK-2017357 | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01709149 |
| Placebo tablets | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT02496767 |
| Tirasemtiv | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT02496767 |
| Placebo tablets | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT02496767 |
| Tirasemtiv | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT02496767 |
| Omecamtiv mecarbil | Other | Phase PHASE3 | Chronic Heart Failure With Reduced Ejection Fraction | WITHDRAWN | NCT04464525 |
| Placebo | Other | Phase PHASE2 | Heart Failure | COMPLETED | NCT00624442 |
| CK-1827452 | Other | Phase PHASE2 | Heart Failure | COMPLETED | NCT00624442 |
| tirasemtiv | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis (ALS) | COMPLETED | NCT02936635 |
| tirasemtiv | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis (ALS) | COMPLETED | NCT02936635 |
| tirasemtiv | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis (ALS) | COMPLETED | NCT02936635 |
| 50 mg Omecamtiv Mecarbil | Other | Phase PHASE2 | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT02695420 |
| 37.5 mg Omecamtiv Mecarbil | Other | Phase PHASE2 | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT02695420 |
| Placebo | Other | Phase PHASE2 | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT02695420 |
| 25 mg Omecamtiv Mecarbil | Other | Phase PHASE2 | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT02695420 |
| 50 mg Omecamtiv Mecarbil | Other | Phase PHASE2 | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT02695420 |
| 37.5 mg Omecamtiv Mecarbil | Other | Phase PHASE2 | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT02695420 |
| Placebo | Other | Phase PHASE2 | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT02695420 |
| 25 mg Omecamtiv Mecarbil | Other | Phase PHASE2 | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT02695420 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT02601001 |
| Omecamtiv mecarbil | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT02601001 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT02601001 |
| Omecamtiv mecarbil | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT02601001 |
| Omecamtiv mecarbil | Other | Phase PHASE2 | Heart Failure | COMPLETED | NCT01300013 |
| Placebo | Other | Phase PHASE2 | Heart Failure | COMPLETED | NCT01300013 |
| Omecamtiv mecarbil | Other | Phase PHASE2 | Heart Failure | COMPLETED | NCT01300013 |
| Placebo | Other | Phase PHASE2 | Heart Failure | COMPLETED | NCT01300013 |
| AMG 423 | Other | Phase PHASE1 | Heart Failure | COMPLETED | NCT01737866 |
| AMG 423 | Other | Phase PHASE1 | Heart Failure | COMPLETED | NCT01737866 |
| AMG 423 | Other | Phase PHASE1 | Heart Failure | COMPLETED | NCT01737866 |
| Omecamtiv mecarbil | Other | Phase PHASE2 | Heart Failure | WITHDRAWN | NCT01077167 |
| Omecamtiv Mecarbil Swellable Core Technology F2 | Other | Phase PHASE2 | Modified Release Oral Formulation | COMPLETED | NCT01786512 |
| Placebo | Other | Phase PHASE2 | Modified Release Oral Formulation | COMPLETED | NCT01786512 |
| Omecamtiv Mecarbil Matrix F2 Formulation | Other | Phase PHASE2 | Modified Release Oral Formulation | COMPLETED | NCT01786512 |
| Omecamtiv Mecarbil Matrix F1 Formulation | Other | Phase PHASE2 | Modified Release Oral Formulation | COMPLETED | NCT01786512 |
| Omecamtiv Mecarbil Swellable Core Technology F2 | Other | Phase PHASE2 | Modified Release Oral Formulation | COMPLETED | NCT01786512 |
| Placebo | Other | Phase PHASE2 | Modified Release Oral Formulation | COMPLETED | NCT01786512 |
| Omecamtiv Mecarbil Matrix F2 Formulation | Other | Phase PHASE2 | Modified Release Oral Formulation | COMPLETED | NCT01786512 |
| Omecamtiv Mecarbil Matrix F1 Formulation | Other | Phase PHASE2 | Modified Release Oral Formulation | COMPLETED | NCT01786512 |
| Standard of Care | Other | Phase PHASE3 | Heart Failure | COMPLETED | NCT02929329 |
| Placebo | Other | Phase PHASE3 | Heart Failure | COMPLETED | NCT02929329 |
| Omecamtiv Mecarbil | Other | Phase PHASE3 | Heart Failure | COMPLETED | NCT02929329 |
| Placebo | Other | Phase PHASE3 | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT03759392 |
| Omecamtiv Mecarbil | Other | Phase PHASE3 | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT03759392 |
| Placebo | Other | Phase PHASE3 | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT03759392 |
| Omecamtiv Mecarbil | Other | Phase PHASE3 | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT03759392 |
| Moxifloxacin | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05924815 |
| Aficamten-matching Placebo | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05924815 |
| Aficamten | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05924815 |
| Moxifloxacin | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05924815 |
| Aficamten-matching Placebo | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05924815 |
| Aficamten | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05924815 |
| Reldesemtiv | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis | TERMINATED | NCT05442775 |
| Placebo for CK-3828136 | Other | Phase PHASE1 | Healthy Participants | TERMINATED | NCT05662215 |
| CK-3828136 | Other | Phase PHASE1 | Healthy Participants | TERMINATED | NCT05662215 |
| Placebo for CK-3828136 | Other | Phase PHASE1 | Healthy Participants | TERMINATED | NCT05662215 |
| CK-3828136 | Other | Phase PHASE1 | Healthy Participants | TERMINATED | NCT05662215 |
| Placebo | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis | TERMINATED | NCT04944784 |
| Reldesemtiv | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis | TERMINATED | NCT04944784 |
| Placebo | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis | TERMINATED | NCT04944784 |
| Reldesemtiv | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis | TERMINATED | NCT04944784 |
| Placebo | Other | Phase PHASE1 | Obstructive Hypertrophic Cardiomyopathy | COMPLETED | NCT04783766 |
| CK-3773274 | Other | Phase PHASE1 | Obstructive Hypertrophic Cardiomyopathy | COMPLETED | NCT04783766 |
| Placebo | Other | Phase PHASE1 | Obstructive Hypertrophic Cardiomyopathy | COMPLETED | NCT04783766 |
| CK-3773274 | Other | Phase PHASE1 | Obstructive Hypertrophic Cardiomyopathy | COMPLETED | NCT04783766 |
| CK-3773274 - Tablets | Other | Phase PHASE1 | Symptomatic Obstructive Hypertrophic Cardiomyopathy | COMPLETED | NCT03767855 |
| Placebo - Granules in Capsule | Other | Phase PHASE1 | Symptomatic Obstructive Hypertrophic Cardiomyopathy | COMPLETED | NCT03767855 |
| CK-3773274 - Granules in Capsule | Other | Phase PHASE1 | Symptomatic Obstructive Hypertrophic Cardiomyopathy | COMPLETED | NCT03767855 |
| CK-3773274 - Tablets | Other | Phase PHASE1 | Symptomatic Obstructive Hypertrophic Cardiomyopathy | COMPLETED | NCT03767855 |
| Placebo - Granules in Capsule | Other | Phase PHASE1 | Symptomatic Obstructive Hypertrophic Cardiomyopathy | COMPLETED | NCT03767855 |
| CK-3773274 - Granules in Capsule | Other | Phase PHASE1 | Symptomatic Obstructive Hypertrophic Cardiomyopathy | COMPLETED | NCT03767855 |
| CK-3773274 - Tablets | Other | Phase PHASE1 | Symptomatic Obstructive Hypertrophic Cardiomyopathy | COMPLETED | NCT03767855 |
| Placebo - Granules in Capsule | Other | Phase PHASE1 | Symptomatic Obstructive Hypertrophic Cardiomyopathy | COMPLETED | NCT03767855 |
| CK-3773274 - Granules in Capsule | Other | Phase PHASE1 | Symptomatic Obstructive Hypertrophic Cardiomyopathy | COMPLETED | NCT03767855 |
| Moxifloxacin | Other | Phase PHASE1 | QT Intervals Changes | COMPLETED | NCT04175808 |
| Placebo | Other | Phase PHASE1 | QT Intervals Changes | COMPLETED | NCT04175808 |
| Omecamtiv Mecarbil (OM) | Other | Phase PHASE1 | QT Intervals Changes | COMPLETED | NCT04175808 |
| Moxifloxacin | Other | Phase PHASE1 | QT Intervals Changes | COMPLETED | NCT04175808 |
| Placebo | Other | Phase PHASE1 | QT Intervals Changes | COMPLETED | NCT04175808 |
| Omecamtiv Mecarbil (OM) | Other | Phase PHASE1 | QT Intervals Changes | COMPLETED | NCT04175808 |
| Placebo for CK-4021586 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05877053 |
| CK-4021586 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05877053 |
| Placebo to match CK-4021586 | Other | Phase PHASE2 | Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) | RECRUITING | NCT06793371 |
| CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg) | Other | Phase PHASE2 | Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) | RECRUITING | NCT06793371 |
| Placebo to match CK-4021586 | Other | Phase PHASE2 | Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) | RECRUITING | NCT06793371 |
| CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg) | Other | Phase PHASE2 | Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) | RECRUITING | NCT06793371 |
| Aficamten (5 - 20 mg) | Other | Phase PHASE2 | Symptomatic Hypertrophic Cardiomyopathy (HCM) | ENROLLING_BY_INVITATION | NCT04848506 |
| Aficamten (5 - 20 mg) | Other | Phase PHASE2 | Symptomatic Hypertrophic Cardiomyopathy (HCM) | ENROLLING_BY_INVITATION | NCT04848506 |
| Placebo | Other | Phase PHASE3 | Heart Failure | RECRUITING | NCT06736574 |
| Omecamtiv Mecarbil (OM) | Other | Phase PHASE3 | Heart Failure | RECRUITING | NCT06736574 |
| Placebo | Other | Phase PHASE3 | Heart Failure | RECRUITING | NCT06736574 |
| Omecamtiv Mecarbil (OM) | Other | Phase PHASE3 | Heart Failure | RECRUITING | NCT06736574 |
| Placebo for CK-3773274 | Other | Phase PHASE2 | Hypertrophic Cardiomyopathy (HCM) | COMPLETED | NCT04219826 |
| CK-3773274 (10 - 30 mg) | Other | Phase PHASE2 | Hypertrophic Cardiomyopathy (HCM) | COMPLETED | NCT04219826 |
| CK-3773274 (5 - 15 mg) | Other | Phase PHASE2 | Hypertrophic Cardiomyopathy (HCM) | COMPLETED | NCT04219826 |
| Placebo for CK-3773274 | Other | Phase PHASE2 | Hypertrophic Cardiomyopathy (HCM) | COMPLETED | NCT04219826 |
| CK-3773274 (10 - 30 mg) | Other | Phase PHASE2 | Hypertrophic Cardiomyopathy (HCM) | COMPLETED | NCT04219826 |
| CK-3773274 (5 - 15 mg) | Other | Phase PHASE2 | Hypertrophic Cardiomyopathy (HCM) | COMPLETED | NCT04219826 |
| Placebo to match aficamten | Other | Phase PHASE3 | Obstructive Hypertrophic Cardiomyopathy (oHCM) | COMPLETED | NCT05186818 |
| Aficamten (5 mg, 10 mg, 15 mg, and 20 mg) | Other | Phase PHASE3 | Obstructive Hypertrophic Cardiomyopathy (oHCM) | COMPLETED | NCT05186818 |
| Placebo to match aficamten | Other | Phase PHASE3 | Obstructive Hypertrophic Cardiomyopathy (oHCM) | COMPLETED | NCT05186818 |
| Aficamten (5 mg, 10 mg, 15 mg, and 20 mg) | Other | Phase PHASE3 | Obstructive Hypertrophic Cardiomyopathy (oHCM) | COMPLETED | NCT05186818 |
| Placebo | Other | Phase PHASE2 | Pediatric | RECRUITING | NCT06412666 |
| Aficamten | Other | Phase PHASE2 | Pediatric | RECRUITING | NCT06412666 |
Total products: 195